Medidata launches Rave automatic SAE reporting add-on

By Staff Reporter

- Last updated on GMT

Related tags: Clinical research, Clinical trial

Medidata says the latest addition to its EDC platform, the Rave Safety Gateway, will cut the time it takes to report adverse events during trials and help CROs and their sponsors comply with increasingly stringent reporting rules.

While the globalisation of the clinical trial sector and increased use of multi-center studies has improved access to diverse populations and opened up emerging markets, it has made all aspects of management more complicated and time consuming.

One of the most critical of these areas to be affected, from both a patient safety and regulatory perspective, has been the collation and reporting of serious adverse events (SAEs), at least, it has according to Medidata.

The firm suggested that: “Today's process of collecting complete and accurate SAE information relies heavily on multiple exchanges including phone conversations, paper forms and faxes between sites and sponsors.

In addition, sites must bear the burden of communicating this information to sponsors via a separate paper process. These laborious and redundant manual efforts are further compounded by the need to reconcile clinical and safety data at the end of a trial​.”

Medidata’s solution to these challenges is the Rave Safety Gateway, which is designed to automatically transmitting safety data from trial sites to sponsors' in the International Conference on Harmonization (ICH) industry standard E2B file format.

This approach, the firm believes, allows streamline reporting efforts in a manner that complies with global regulatory requirement and significantly reduces the burden of collecting and reconciling safety data.

Medidata president Glen de Vries “Rave Safety Gateway enables our customers to build a fully electronic, standards-based process to submit all SAE-related data captured in EDC to the safety system of their choice with minimal effort.”

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Global Clinical Trial Lab Services

Global Clinical Trial Lab Services

Q2 Solutions | 01-Apr-2020 | Product Presentation

As a leading global lab services partner, we provide operational excellence, scientific leadership and innovation through technology. We offer end-to-end...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us


View more